Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 5,020 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Cancers
Interventions
Temsirolimus, Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
14 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Riverside, California + 16 more
Conditions
Colitis, Ulcerative
Interventions
placebo, MultiStem low dose, MultiStem high dose
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
37
States / cities
San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more
Conditions
Safety Issues, Pain, Pancreas Fibrosis
Interventions
Proglumide, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Mucosal Melanoma, Recurrent Melanoma, Recurrent Uveal Melanoma, Stage IIIA Skin Melanoma, Stage IIIA Uveal Melanoma, Stage IIIB Skin Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Skin Melanoma, Stage IIIC Uveal Melanoma, Stage IV Skin Melanoma, Stage IV Uveal Melanoma
Interventions
Epacadostat, MELITAC 12.1 Peptide Vaccine
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Durham, North Carolina • Cleveland, Ohio + 1 more
Conditions
Breast Cancer, Cancer of the Breast
Interventions
VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based Prosigna breast cancer gene signature assay, Anastrozole, Combination anthracycline and/or taxane based treatment
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Anxiety, Depression
Interventions
App for smartphone, smartphone
Behavioral · Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers

Program to Overcome Pelvic Pain With Yoga

NCT02261740
Conditions
Pelvic Pain
Interventions
Yoga Therapy
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

NCT01313728
Conditions
Acne Vulgaris
Interventions
Dapsone plus Tretinoin Gel, Tretinoin Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Broomall, Pennsylvania
Conditions
Wrinkle
Interventions
Botulinum toxin type A
Drug
Lead sponsor
Global Aesthetics LLC
Other
Eligibility
20 Years to 65 Years
Timeline
2024 – 2027
U.S. locations
2
States / cities
Cisco, Texas • Lubbock, Texas
Conditions
Multiple Myeloma
Interventions
Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Chronic Kidney Diseases
Interventions
Best practice alert and order set for CKD
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Inherited Retinal Diseases
Interventions
Low Vision Rehabilitation (LVR), Emotion Regulation Therapy (ERT)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Hand Eczema
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Encino, California • Fountain Valley, California + 22 more
Conditions
Solid Tumor, Adult, Oncology
Interventions
TRE-515
Drug
Lead sponsor
Trethera
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Santa Monica, California • Huntersville, North Carolina
Conditions
Gout Chronic, Gout, DDI (Drug-Drug Interaction)
Interventions
ABP-671 plus allopurinol
Drug
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cary, North Carolina
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography, Magnetic Resonance Imaging, Bone Scan, Electronic Health Record Review
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Hodgkin Lymphoma, Relapse, Refractory
Interventions
Chemotherapy, Cell infusion
Drug · Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Desmoid Tumor
Interventions
methotrexate, vinblastine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 28 more
Completed Phase 2Phase 3 Interventional

Risk Reduction for Alzheimer's Disease

NCT02913664
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions
Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more
Conditions
Desmoid Tumor
Interventions
tamoxifen citrate, sulindac, laboratory biomarker analysis
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Monrovia, California
Conditions
AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
Interventions
Rabbit Anti thymocyte globulin, Busulfan, Fludarabine, Thiotepa, Melphalan, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, memory-like natural killer cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, CliniMACS
Drug · Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri